jorge pinto

Jorge Pinto has extensive work experience in the field of pharmaceutical technology and research. jorge began their career in 2012 as a PhD student conducting research internships at the National Institutes of Health. During their time there, they focused on the production and purification of a recombinant HPV-16 L2 protein, as well as the design and development of a nanoemulsion as an adjuvant system for the protein. jorge also worked on the association of the L2 protein to the nanoemulsion to create a prototype HPV vaccine.

In 2013, Jorge continued their PhD studies at the National Institutes of Health, where they worked on the design and development of a nanoparticle integrating Poly (I:C), PADRE, and a HPV-16 L2 synthetic peptide-based antigen. jorge conducted experiments involving the administration of the HPV vaccine prototype in mice and evaluated the resulting humoral response.

After completing their PhD, Jorge joined the Universidad de Santiago de Compostela as a post-doctoral researcher from May to August 2015. jorge then worked as a PhD student at the university from January 2009 to June 2015.

In 2016, Jorge joined Arecor Limited as a scientist, where they were responsible for formulation development programs. jorge later moved into a senior scientist role and eventually became the team leader for technology partnering. In this position, they managed a team of seven scientists and oversaw the delivery of Arecor technology programs with pharmaceutical partners. jorge also handled relationships with stakeholders, including pharma or biotech partners, external alliances, and the management team.

Overall, Jorge Pinto's work experience has predominantly focused on pharmaceutical research and technology development, with a specialization in HPV vaccines.

Jorge Pinto completed their education in two prestigious universities. From 2002 to 2008, they attended Universidade de Coimbra, where they earned a Master's degree in Pharmaceutical Science. Later, from 2009 to 2015, they pursued a Doctor of Philosophy (PhD) in Pharmaceutical Sciences at Universidad de Santiago de Compostela. Their PhD specialization was in the field of Nanomedicine and Vaccines.